A detailed history of Goldman Sachs Group Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Goldman Sachs Group Inc holds 941,490 shares of NVCR stock, worth $21.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
941,490
Previous 785,745 19.82%
Holding current value
$21.2 Million
Previous $12.3 Million 128.45%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$14.54 - $33.41 $2.26 Million - $5.2 Million
155,745 Added 19.82%
941,490 $28.1 Million
Q3 2024

Nov 14, 2024

BUY
$15.61 - $23.34 $8.5 Million - $12.7 Million
544,232 Added 225.34%
785,745 $12.3 Million
Q2 2024

Aug 13, 2024

SELL
$11.83 - $24.05 $1.05 Million - $2.13 Million
-88,391 Reduced 26.79%
241,513 $4.14 Million
Q1 2024

May 15, 2024

BUY
$12.42 - $17.29 $111,556 - $155,298
8,982 Added 2.8%
329,904 $5.16 Million
Q4 2023

Feb 13, 2024

BUY
$11.13 - $15.78 $2.17 Million - $3.08 Million
195,079 Added 155.02%
320,922 $4.79 Million
Q3 2023

May 14, 2024

SELL
$16.15 - $42.35 $3.15 Million - $8.26 Million
-195,079 Reduced 60.79%
125,843 $2.03 Million
Q3 2023

Nov 14, 2023

BUY
$16.15 - $42.35 $212,776 - $557,961
13,175 Added 11.69%
125,843 $2.03 Million
Q2 2023

May 14, 2024

SELL
$40.29 - $82.51 $1.61 Million - $3.3 Million
-39,951 Reduced 26.18%
112,668 $4.68 Million
Q2 2023

Aug 14, 2023

SELL
$40.29 - $82.51 $1.61 Million - $3.3 Million
-39,951 Reduced 26.18%
112,668 $4.68 Million
Q1 2023

May 14, 2024

SELL
$56.44 - $118.81 $6.77 Million - $14.3 Million
-120,014 Reduced 44.02%
152,619 $9.18 Million
Q1 2023

May 11, 2023

SELL
$56.44 - $118.81 $6.77 Million - $14.3 Million
-120,014 Reduced 44.02%
152,619 $9.18 Million
Q4 2022

May 14, 2024

BUY
$63.98 - $85.37 $194,243 - $259,183
3,036 Added 1.13%
272,633 $20 Million
Q4 2022

Feb 13, 2023

BUY
$63.98 - $85.37 $194,243 - $259,183
3,036 Added 1.13%
272,633 $20 Million
Q3 2022

May 14, 2024

BUY
$67.99 - $89.57 $1.27 Million - $1.67 Million
18,626 Added 7.42%
269,597 $20.5 Million
Q3 2022

Nov 10, 2022

BUY
$67.99 - $89.57 $1.27 Million - $1.67 Million
18,626 Added 7.42%
269,597 $20.5 Million
Q2 2022

May 14, 2024

SELL
$56.6 - $89.9 $3.96 Million - $6.29 Million
-69,951 Reduced 21.8%
250,971 $17.4 Million
Q2 2022

Aug 15, 2022

BUY
$56.6 - $89.9 $2.69 Million - $4.27 Million
47,517 Added 23.36%
250,971 $17.4 Million
Q1 2022

May 16, 2022

SELL
$60.15 - $84.52 $6.34 Million - $8.92 Million
-105,480 Reduced 34.14%
203,454 $16.9 Million
Q4 2021

Feb 14, 2022

BUY
$75.08 - $121.99 $6.19 Million - $10.1 Million
82,446 Added 36.4%
308,934 $23.2 Million
Q3 2021

Nov 10, 2021

BUY
$116.17 - $194.55 $26.3 Million - $44.1 Million
226,488 New
226,488 $26.3 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $2.36B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.